Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 1.8% – Should You Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s stock price rose 1.8% on Tuesday . The company traded as high as $4.18 and last traded at $4.00. 77,890 shares traded hands during mid-day trading, an increase of 143% from the average daily volume of 32,010 shares. The stock had previously closed at $3.93.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Cyclerion Therapeutics Price Performance

The company has a market cap of $18.82 million, a PE ratio of -2.42 and a beta of 1.76. The business has a 50 day moving average of $3.61 and a 200 day moving average of $2.90.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($7.10) by $6.69. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 87.96%. Sell-side analysts forecast that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclerion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP bought a new position in shares of Cyclerion Therapeutics during the third quarter valued at $31,000. BlackRock Inc. purchased a new stake in Cyclerion Therapeutics during the second quarter valued at $57,000. Braidwell LP purchased a new position in Cyclerion Therapeutics in the second quarter worth about $532,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Cyclerion Therapeutics in the 2nd quarter worth approximately $1,013,000. Institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.